Not Yet Recruiting ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma NCT07505849 Conditions Follicular Lymphomas, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more Locations Not specified View Trial Details
Completed Bendamustine Plus Rituximab Versus CHOP Plus Rituximab NCT00991211 Conditions Chronic Disease, Disease Attributes, Follicular Lymphomas, +21 more Locations StiL Head Office; Justus-Liebig-University — Giessen, Germany View Trial Details
Completed Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas NCT02650999 Conditions CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Hemic and Lymphatic Diseases, +11 more Locations Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States View Trial Details
Completed Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 Conditions Acute Lymphocytic Leukemia, Acute Myelocytic Leukemia, Bone Marrow Diseases, +51 more Locations Novartis Investigative Site — Minneapolis, Minnesota, United States View Trial Details
Active, Not Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas NCT00877214 Conditions Chronic Disease, Disease Attributes, Follicular Lymphomas, +23 more Locations StiL Head Office; Justus-Liebig-University — Giessen, Germany View Trial Details
